Welcome to our dedicated page for ELOXD SEC filings (Ticker: ELOXD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELOXD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELOXD's regulatory disclosures and financial reporting.
Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Eloxx Pharmaceuticals reported that certain affiliated investment entities led by Invus and Avicenna hold aggregate beneficial interests in its common stock. As of June 9, 2026, the Reporting Persons beneficially owned 403,586 shares (an aggregate of 400,000 shares and 3,586 warrants) representing 9.99% of issued and outstanding shares. The filing states Invus Public Equities directly held 350,525 shares and 43,816 pre-funded warrants, and Avicenna Fund directly held 49,475 shares and 6,184 pre-funded warrants. Shares outstanding used for the percentage calculation were 4,036,314 as of June 10, 2026. A Beneficial Ownership Limitation prevents exercises that would exceed 9.99%.
Eloxx Pharmaceuticals reported that certain affiliated investment entities led by Invus and Avicenna hold aggregate beneficial interests in its common stock. As of June 9, 2026, the Reporting Persons beneficially owned 403,586 shares (an aggregate of 400,000 shares and 3,586 warrants) representing 9.99% of issued and outstanding shares. The filing states Invus Public Equities directly held 350,525 shares and 43,816 pre-funded warrants, and Avicenna Fund directly held 49,475 shares and 6,184 pre-funded warrants. Shares outstanding used for the percentage calculation were 4,036,314 as of June 10, 2026. A Beneficial Ownership Limitation prevents exercises that would exceed 9.99%.